Recent Advances in Cancer Cell Membrane‐Based Nanoparticles and Cancer Cell‐Derived Small Extracellular Vesicles as Drug Delivery Platforms
Advances in nanotechnology have paved the way for innovative drug delivery systems that enhance the effectiveness of cancer treatment. Cancer cell membrane‐based nanoparticles (CCM‐NPs) and cancer cell‐derived small extracellular vesicles (CsEVs) are emerging as promising drug delivery systems for c...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley-VCH
2025-06-01
|
| Series: | Advanced NanoBiomed Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/anbr.202500008 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849335794274140160 |
|---|---|
| author | Wei Zhang Jingjing Wang Long Ngo Li Li Yuling Wang |
| author_facet | Wei Zhang Jingjing Wang Long Ngo Li Li Yuling Wang |
| author_sort | Wei Zhang |
| collection | DOAJ |
| description | Advances in nanotechnology have paved the way for innovative drug delivery systems that enhance the effectiveness of cancer treatment. Cancer cell membrane‐based nanoparticles (CCM‐NPs) and cancer cell‐derived small extracellular vesicles (CsEVs) are emerging as promising drug delivery systems for cancer treatment due to their inherent properties such as low immunogenicity and natural targeting capabilities to cancer cells. However, a comprehensive comparison of the advantages, disadvantages, and similarities of these two platforms is lacking. This review summarizes the natural, engineered, and hybrid forms of CCM‐NPs and CsEVs‐based drug delivery platforms with a focus on comparison of these two platforms, considering key aspects including preparation methods, drug encapsulation strategies, delivery pathways, immune evasion, targeting ability, and their potential for clinical applications. By understanding the strengths and weaknesses of each approach, the aim is to pave the way for next‐generation nanoscale drug delivery platforms and contribute to the development of more effective and personalized cancer therapies. |
| format | Article |
| id | doaj-art-d2a41e7e03d34409bbd86f1916c909f0 |
| institution | Kabale University |
| issn | 2699-9307 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Wiley-VCH |
| record_format | Article |
| series | Advanced NanoBiomed Research |
| spelling | doaj-art-d2a41e7e03d34409bbd86f1916c909f02025-08-20T03:45:10ZengWiley-VCHAdvanced NanoBiomed Research2699-93072025-06-0156n/an/a10.1002/anbr.202500008Recent Advances in Cancer Cell Membrane‐Based Nanoparticles and Cancer Cell‐Derived Small Extracellular Vesicles as Drug Delivery PlatformsWei Zhang0Jingjing Wang1Long Ngo2Li Li3Yuling Wang4School of Natural Sciences Faculty of Science and Engineering Macquarie University Sydney NSW 2109 AustraliaAustralian Institute for Bioengineering and Nanotechnology University of Queensland Brisbane QLD 4072 AustraliaSchool of Natural Sciences Faculty of Science and Engineering Macquarie University Sydney NSW 2109 AustraliaAustralian Institute for Bioengineering and Nanotechnology University of Queensland Brisbane QLD 4072 AustraliaSchool of Natural Sciences Faculty of Science and Engineering Macquarie University Sydney NSW 2109 AustraliaAdvances in nanotechnology have paved the way for innovative drug delivery systems that enhance the effectiveness of cancer treatment. Cancer cell membrane‐based nanoparticles (CCM‐NPs) and cancer cell‐derived small extracellular vesicles (CsEVs) are emerging as promising drug delivery systems for cancer treatment due to their inherent properties such as low immunogenicity and natural targeting capabilities to cancer cells. However, a comprehensive comparison of the advantages, disadvantages, and similarities of these two platforms is lacking. This review summarizes the natural, engineered, and hybrid forms of CCM‐NPs and CsEVs‐based drug delivery platforms with a focus on comparison of these two platforms, considering key aspects including preparation methods, drug encapsulation strategies, delivery pathways, immune evasion, targeting ability, and their potential for clinical applications. By understanding the strengths and weaknesses of each approach, the aim is to pave the way for next‐generation nanoscale drug delivery platforms and contribute to the development of more effective and personalized cancer therapies.https://doi.org/10.1002/anbr.202500008cancer treatmentcell membranedrug deliveryextracellular vesiclesexosomes |
| spellingShingle | Wei Zhang Jingjing Wang Long Ngo Li Li Yuling Wang Recent Advances in Cancer Cell Membrane‐Based Nanoparticles and Cancer Cell‐Derived Small Extracellular Vesicles as Drug Delivery Platforms Advanced NanoBiomed Research cancer treatment cell membrane drug delivery extracellular vesicles exosomes |
| title | Recent Advances in Cancer Cell Membrane‐Based Nanoparticles and Cancer Cell‐Derived Small Extracellular Vesicles as Drug Delivery Platforms |
| title_full | Recent Advances in Cancer Cell Membrane‐Based Nanoparticles and Cancer Cell‐Derived Small Extracellular Vesicles as Drug Delivery Platforms |
| title_fullStr | Recent Advances in Cancer Cell Membrane‐Based Nanoparticles and Cancer Cell‐Derived Small Extracellular Vesicles as Drug Delivery Platforms |
| title_full_unstemmed | Recent Advances in Cancer Cell Membrane‐Based Nanoparticles and Cancer Cell‐Derived Small Extracellular Vesicles as Drug Delivery Platforms |
| title_short | Recent Advances in Cancer Cell Membrane‐Based Nanoparticles and Cancer Cell‐Derived Small Extracellular Vesicles as Drug Delivery Platforms |
| title_sort | recent advances in cancer cell membrane based nanoparticles and cancer cell derived small extracellular vesicles as drug delivery platforms |
| topic | cancer treatment cell membrane drug delivery extracellular vesicles exosomes |
| url | https://doi.org/10.1002/anbr.202500008 |
| work_keys_str_mv | AT weizhang recentadvancesincancercellmembranebasednanoparticlesandcancercellderivedsmallextracellularvesiclesasdrugdeliveryplatforms AT jingjingwang recentadvancesincancercellmembranebasednanoparticlesandcancercellderivedsmallextracellularvesiclesasdrugdeliveryplatforms AT longngo recentadvancesincancercellmembranebasednanoparticlesandcancercellderivedsmallextracellularvesiclesasdrugdeliveryplatforms AT lili recentadvancesincancercellmembranebasednanoparticlesandcancercellderivedsmallextracellularvesiclesasdrugdeliveryplatforms AT yulingwang recentadvancesincancercellmembranebasednanoparticlesandcancercellderivedsmallextracellularvesiclesasdrugdeliveryplatforms |